NYSE:PKI - PerkinElmer Stock Price, Forecast & News

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

PerkinElmer announced a quarterly dividend on Thursday, October 24th. Investors of record on Friday, January 17th will be paid a dividend of $0.07 per share on Friday, February 7th. This represents a $0.28 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Thursday, January 16th. View PerkinElmer's Dividend History.

PerkinElmer, Inc. (NYSE:PKI) posted its quarterly earnings data on Wednesday, October, 30th. The medical research company reported $1.06 EPS for the quarter, beating the consensus estimate of $1.01 by $0.05. The medical research company had revenue of $706.92 million for the quarter, compared to the consensus estimate of $722.69 million. PerkinElmer had a return on equity of 16.45% and a net margin of 8.27%. The company's revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.90 earnings per share. View PerkinElmer's Earnings History.

PerkinElmer is scheduled to release their next quarterly earnings announcement on Monday, January 27th 2020. View Earnings Estimates for PerkinElmer.

PerkinElmer will be holding an earnings conference call on Monday, January 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PerkinElmer issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided earnings per share (EPS) guidance of $4.07 for the period, compared to the Thomson Reuters consensus EPS estimate of $4.03.

13 brokers have issued twelve-month price objectives for PerkinElmer's shares. Their forecasts range from $41.00 to $115.00. On average, they expect PerkinElmer's stock price to reach $84.46 in the next year. This suggests that the stock has a possible downside of 16.8%. View Analyst Price Targets for PerkinElmer.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

Press coverage about PKI stock has been trending neutral on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. PerkinElmer earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media stories about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for PerkinElmer.

Some companies that are related to PerkinElmer include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Cambrex (CBM), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include NVIDIA (NVDA), AbbVie (ABBV), IBM (IBM), Visa (V), Alibaba Group (BABA), salesforce.com (CRM), Thermo Fisher Scientific (TMO), Adobe (ADBE), Cisco Systems (CSCO) and Home Depot (HD).

PerkinElmer's stock is owned by a number of of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (0.19%), Boston Trust Walden Corp (0.14%), First National Bank of Omaha (0.08%), Nisa Investment Advisors LLC (0.07%), Commerzbank Aktiengesellschaft FI (0.03%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

PKI stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Nisa Investment Advisors LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, State of Alaska Department of Revenue, Tributary Capital Management LLC and Wealthfront Advisers LLC. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Pascale Witz, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

PKI stock was bought by a variety of institutional investors in the last quarter, including Johanson Financial Advisors Inc., First Hawaiian Bank, Boston Trust Walden Corp, Zurcher Kantonalbank Zurich Cantonalbank , AE Wealth Management LLC, Rockland Trust Co., Prentiss Smith & Co. Inc. and Commerzbank Aktiengesellschaft FI. View Insider Buying and Selling for PerkinElmer.

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PKI stock can currently be purchased for approximately $101.49.

PerkinElmer has a market capitalization of $11.28 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

The official website for PerkinElmer is http://www.perkinelmer.com/.

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]